The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | Novel strategies to treating brain metastases in lung cancer
Amreen Ahmed, FRCP, MD, MBBS, MSc (onc), University Hospitals of Leicester, Leicester, UK, outlines the emerging approaches to brain metastases associated with lung cancer, specifically the switch to considering systemic treatment for these rather than the usual multi-modality treatment model. Emerging therapeutics in this space are targeted therapies, with good CNS penetration being a necessary characteristic for an effective treatment. Lorlatinib is one such therapeutic, an inhibitor employed to treat lung cancer with ALK mutations. A 70-80% complete response has been noted following this systemic treatment. Osimertinib, amivantamab and lazertinib are all similar targeted therapies being studied and employed in the treatment of EGFR-driven lung cancer. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
